SG 301
Alternative Names: SG-301; SG-301 SCLatest Information Update: 03 Mar 2025
At a glance
- Originator Hangzhou Sumgen Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD38 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies; Multiple myeloma; Systemic lupus erythematosus
Most Recent Events
- 07 Dec 2024 Adverse events, efficacy and pharmacodynamics data from a phase I trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 29 Sep 2023 Phase-I clinical trials in Systemic lupus erythematosus in China (SC)
- 29 Jun 2023 National Medical Products Administration (NMPA) approves Clinical trial application for SG 301 in Systemic lupus erythematosus (SC, Injection) in China